Puma Biotechnology, Inc. (PBYI)
PBYI Stock Price Chart
Explore Puma Biotechnology, Inc. interactive price chart. Choose custom timeframes to analyze PBYI price movements and trends.
PBYI Company Profile
Discover essential business fundamentals and corporate details for Puma Biotechnology, Inc. (PBYI) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
24 Apr 2012
Employees
172.00
CEO
Alan H. Auerbach
Description
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
PBYI Financial Timeline
Browse a chronological timeline of Puma Biotechnology, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is $0.04, while revenue estimate is $53.00m.
Earnings released on 7 May 2026
EPS came in at -$0.04 surpassing the estimated -$0.13 by +69.23%, while revenue for the quarter reached $44.80m , beating expectations by +6.67%.
Earnings released on 26 Feb 2026
EPS came in at $0.29 surpassing the estimated $0.24 by +20.83%, while revenue for the quarter reached $59.90m , missing expectations by -12.71%.
Earnings released on 6 Nov 2025
EPS came in at $0.21 surpassing the estimated $0.09 by +133.33%, while revenue for the quarter reached $54.48m , missing expectations by -20.59%.
Earnings released on 7 Aug 2025
EPS came in at $0.15 surpassing the estimated $0.11 by +36.36%, while revenue for the quarter reached $52.44m , beating expectations by +2.82%.
Earnings released on 8 May 2025
EPS came in at $0.10 surpassing the estimated $0.02 by +400.00%, while revenue for the quarter reached $46.01m , missing expectations by -12.78%.
Earnings released on 27 Feb 2025
EPS came in at $0.43 surpassing the estimated $0.10 by +330.00%, while revenue for the quarter reached $59.08m , beating expectations by +12.53%.
Earnings released on 7 Nov 2024
EPS came in at $0.41 surpassing the estimated $0.35 by +17.14%, while revenue for the quarter reached $80.54m , beating expectations by +53.41%.
Earnings released on 1 Aug 2024
EPS came in at -$0.05 surpassing the estimated -$0.10 by +50.00%, while revenue for the quarter reached $47.08m , beating expectations by +5.33%.
Earnings released on 2 May 2024
EPS came in at -$0.05 surpassing the estimated -$0.16 by +68.75%, while revenue for the quarter reached $43.77m , beating expectations by +6.62%.
Earnings released on 29 Feb 2024
EPS came in at $0.26 falling short of the estimated $0.30 by -13.33%, while revenue for the quarter reached $72.18m , missing expectations by -1.87%.
Earnings released on 2 Nov 2023
EPS came in at $0.12 surpassing the estimated $0.08 by +50.00%, while revenue for the quarter reached $56.12m , missing expectations by -23.70%.
Earnings released on 3 Aug 2023
EPS came in at $0.10 surpassing the estimated $0.07 by +42.86%, while revenue for the quarter reached $54.57m , beating expectations by +5.49%.
Earnings released on 4 May 2023
EPS came in at $0.09 surpassing the estimated $0.04 by +142.85%, while revenue for the quarter reached $52.78m , beating expectations by +6.34%.
Earnings released on 2 Mar 2023
EPS came in at -$0.12 falling short of the estimated $0.06 by -300.00%, while revenue for the quarter reached $65.70m , beating expectations by +15.14%.
Earnings released on 3 Nov 2022
EPS came in at -$0.01 surpassing the estimated -$0.11 by +90.91%, while revenue for the quarter reached $57.10m , beating expectations by +13.15%.
Earnings released on 4 Aug 2022
EPS came in at $0.21 surpassing the estimated $0.00 by +14.09k%, while revenue for the quarter reached $59.52m , beating expectations by +13.10%.
Earnings released on 5 May 2022
EPS came in at -$0.08 surpassing the estimated -$0.13 by +38.46%, while revenue for the quarter reached $45.74m , beating expectations by +1.49%.
Earnings released on 3 Mar 2022
EPS came in at $0.10 surpassing the estimated -$0.09 by +211.11%, while revenue for the quarter reached $55.40m , beating expectations by +17.46%.
Earnings released on 4 Nov 2021
EPS came in at -$1.09 falling short of the estimated -$0.23 by -373.91%, while revenue for the quarter reached $46.25m , missing expectations by -16.01%.
Earnings released on 5 Aug 2021
EPS came in at -$0.13 surpassing the estimated -$0.31 by +58.06%, while revenue for the quarter reached $53.38m , beating expectations by +0.72%.
PBYI Stock Performance
Access detailed PBYI performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
